Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 542

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 542
---
 payment obligations under the CAR-T License and the Vaccine License. See Note 7 for discussion on funding commitments on the Note.

<div align='center'>F-84</div>

TABLE OF CONTENTS

#### LIMINATUS PHARMA, LLC

### NOTES TO FINANCIAL STATEMENTSDECEMBER 31, 2023 AND 2022

#### Note 9. Subsequent Events
The Company has completed an evaluation of all subsequent events through May 13, 2024, the date the financial statements are available to be issued to ensure that these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements.

On January 5, 2024, the Company funded an additional advance under the Note of $0.7 million, which resulted in a total outstanding principal balance of $1.5 million.

On January 5, 2024, January 8, 2024, and January 22, 2024, the Company borrowed additional amounts from Valetudo totaling $0.8 million.

On February 28, 2024, the Company amended and restated the Note with Iris (the “Amended Note”). The Amended Note increased the principal amount from $1.5 million to $2.5 million.

On March 6, 2024, the Company borrowed an additional $0.3 million from Prophase.

On March 9, 2024, the Company entered into a third amendment to the Business Combination Agreement extending the outside date to July 31, 2024.

On April 2, 2024, the Company funded an additional advance under the Amended Note of $0.3 million.

On May 1, 2024, the Company borrowed an additional $0.1 million from Prophase.

On May 7, 2024, the Company funded an additional advance under the Amended Note of $0.03 million.

On May 13, 2024, the Company borrowed an additional $0.2 million from Prophase, and funded an additional advance under the Amended Note of $0.2 million.

<div align='center'>F-85</div>

TABLE OF CONTENTS

#### Annex A​

### BUSINESS COMBINATION AGREEMENT
<div align='center'>by and among</div>

#### IRIS ACQUISITION CORP,

#### IRIS PARENT HOLDING CORP.,

#### SPAC MERGER SUB,